BMS-908228

Phase 1

BMS-908228 is one of 31 therapeutic programs targeting Enteropathy-Associated T-Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[1]

Indication

Enteropathy-Associated T-Cell LymphomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Enteropathy-Associated T-Cell LymphomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

31 2

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 4

Tibsovo

SServier

Phase 3

8 5

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 3

1 6

Campath

GGenzyme, a Sanofi Company

Salvage Chemotherapy

1 8

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

1 9

Recombinant FLT3 Ligand

EEastern Cooperative Oncology Group

Phase 3

1 10

APG-2575

Ascentage Pharma Group Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Sources

References

[1]
Open Targets Platform — Drug–disease associations for BMS-908228. EMBL-EBI & Wellcome Sanger Institute.
[2]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1
Company: Bristol-Myers Squibb

BMS-908228

Status by Indication[1]

Competitive Landscape

References

Drug Info

Quick Facts

Related News